Last reviewed · How we verify
alpha-blocker or 5-ARI withdrawal
Alpha-blockers block alpha-1 adrenergic receptors, causing smooth muscle relaxation and vasodilation.
Alpha-blockers block alpha-1 adrenergic receptors, causing smooth muscle relaxation and vasodilation. Used for Benign prostatic hyperplasia (BPH), Hypertension.
At a glance
| Generic name | alpha-blocker or 5-ARI withdrawal |
|---|---|
| Also known as | alpha-blocker withdrawal, 5-ARI withdrawal |
| Sponsor | Gangnam Severance Hospital |
| Drug class | alpha-blocker |
| Target | alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Alpha-blockers, such as tamsulosin, work by selectively blocking alpha-1 adrenergic receptors in the smooth muscle of the prostate and bladder neck, leading to relaxation of these muscles and decreased resistance to urine flow. This results in improved urinary symptoms in men with benign prostatic hyperplasia (BPH).
Approved indications
- Benign prostatic hyperplasia (BPH)
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Orthostatic hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alpha-blocker or 5-ARI withdrawal CI brief — competitive landscape report
- alpha-blocker or 5-ARI withdrawal updates RSS · CI watch RSS
- Gangnam Severance Hospital portfolio CI